Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib ...

Amgen has reported positive phase 3 results with ... nocturnal hemoglobinuria (PNH), one if the indications on Soliris' label, and showed that there was no difference between the biosimilar ...

Given the data below, I believe it has high potential to expand its label and become ... when analyzing pharmaceutical companies, has also not disappointed, even as Amgen's R&D expenses continue ...

part of a law pharmaceutical companies have pledged to revisit with the Trump administration. Future of Healthcategory· January 16, 2025 US FDA approves Amgen's colorectal cancer therapy The U.S ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire ... which the British pharma believes may be dosed once every six months. The candidate was originally licensed ...